Diagnosis and treatment of disseminated intravascular coagulation

International Journal of Laboratory Hematology

Volumn 36, Issue 3, 2014, Pages 228-236

  Levi, M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Activated protein C; Antithrombin; Coagulation factors; Disseminated intravascular coagulation; Fibrin degradation products; Platelets; Thrombomodulin; Tissue factor

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; ENDOTHELIAL PROTEIN C RECEPTOR; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN CONCENTRATE; FIBRINOPEPTIDE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN ACTIVATION PEPTIDE; THROMBOCYTE CONCENTRATE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRIN FORMATION; FIBRINOGEN METABOLISM; FIBRINOLYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LATEX AGGLUTINATION TEST; LIVER FUNCTION; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; VALIDATION STUDY; VENOUS THROMBOEMBOLISM; VITAMIN K DEFICIENCY; BLOOD CLOTTING TEST; DISSEMINATED INTRAVASCULAR COAGULATION;

BLOOD COAGULATION TESTS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS;

EID: 84898683674     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12221     Document Type: Review

References (58)

1. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92.
2. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145:24-33.
3. Levi M, Meijers JC. DIC: which laboratory tests are most useful. Blood Rev 2011;25:33-7.
4. Levi M, van der Poll T, Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med 2012;70:114-20.
5. Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, Bobbaers H. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000;28:1871-6.
6. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002;30:1765-71.
7. Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999;115:1363-70.
8. Akca S, Haji Michael P, de Medonca A, Suter PM, Levi M, Vincent JL. The time course of platelet counts in critically ill patients. Crit Care Med 2002;30:753-6.
9. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006;10:222.
10. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003;55:39-44.
11. Greaves M, Preston FE. Approach to the bleeding patient. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th edn. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds). Philadelphia: Lippingcott William & Wilkins; 2001: 1031-43.
12. Kitchen S, Preston FE. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999;25:17-25.
13. Keeling D. International Normalized Ratio in patients not on vitamin K antagonists. J Thromb Haemost 2007;5:188-9.
14. Lowenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010;68:242-51.
15. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004;32:2416-21.
16. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999;82:673-83.
17. McCarron BI, Marder VJ, Kanouse JJ, Francis CW. A soluble fibrin standard: comparable dose-response with immunologic and functional assays. Thromb Haemost 1999;82:145-8.
18. Westerlund E, Woodhams BJ, Eintrei J, Soderblom L, Antovic JP. The evaluation of two automated soluble fibrin assays for use in the routine hospital laboratory. Int J Lab Hematol 2013;35:666-71.
19. Hatada T, Wada H, Kawasugi K, Okamoto K, Uchiyama T, Kushimoto S, Seki Y, Okamura T, Imai H, Kaneko T, Nobori T. Analysis of the cutoff values in fibrin-related markers for the diagnosis of overt DIC. Clin Appl Thromb Hemost 2012;18:495-500.
20. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002;121:1262-8.
21. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
22. Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. [Review] [113 refs]. Blood Rev 1990;4:25-40.
23. Gando S, Nanzaki S, Sasaki S, Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998;79:1111-5.
24. Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989;43:22-8.
25. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
26. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-8.
27. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001;97:1685-8.
28. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
29. Schouten M, van 't Veer C, van der Poll T, Levi M. Effect of the factor V Leiden mutation on the incidence and outcome of severe infection and sepsis. Neth J Med 2012;70:306-10.
30. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-93.
31. Gando S, Kameue T, Morimoto Y, Matsuda M, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002;30:1729-34.
32. Biemond BJ, Levi M, ten Cate H, van der Poll T, Buller HR, Hack CE, ten Cate J. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Colch) 1995;88:587-94.
33. Levi M, Roem D, Kamp AM, de Boer J, Hack CE, ten Cate J. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993;69:141-6.
34. Levi M, de Boer J, Roem D, ten Cate J, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992;67:111-6.
35. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996;75:902-7.
36. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999;354:556-60.
37. Nossel HL, Yudelman I, Canfield RE, Butler VPJ, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54:43-53.
38. Dempfle CE, Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008;34:445-50.
39. Johansson PI, Stensballe J, Vindelov N, Perner A, Espersen K. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 2010;21:168-74.
40. Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, Wolf SE, Mann KG, Holcomb JB. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009;67:266-75.
41. Collins PW, Macchiavello LI, Lewis SJ, Macartney NJ, Saayman AG, Luddington R, Baglin T, Findlay GP. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006;135:220-7.
42. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
43. Wada H, Hatada T, Okamoto K, Uchiyama T, Kawasugi K, Mayumi T, Gando S, Kushimoto S, Seki Y, Madoiwa S, Okamura T, Toc CH. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol 2010;85:691-4.
44. Kim HK, Hong KH, Toh CH. Application of the international normalized ratio in the scoring system for disseminated intravascular coagulation. J Thromb Haemost 2010;8:1116-8.
45. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001;27:657-66.
46. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a five year overview. J Thromb Haemost 2007;5:604-6.
47. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 2009;22:129-36.
48. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009;23:167-76.
49. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924-33.
50. Wada H, Gabazza EC, Asakura H, Koike K, Okamoto K, Maruyama I, Shiku H, Nobori T. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003;74:17-22.
51. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005;33:341-8.
52. Kinasewitz GT, Zein JG, Lee GL, Nazir SR, Taylor FB Jr. Prognostic value of a simple evolving DIC score in patients with severe sepsis. Crit Care Med 2005;33:2214-21.
53. Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med 2013;8:23-32.
54. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007;176:483-90.
55. Levi M, van der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013;79:294-8.
56. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.
57. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
58. Thachil J, Toh CH, Levi M, Watson HG. The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation]. Br J Haematol 2012;157:493-4.